[Subclinical hyperthyroidism: from diagnosis to treatment].

Area of Science:

• Endocrinology
• Internal Medicine

Context:

• Subclinical hyperthyroidism is a common endocrine disorder.
• It is defined by suppressed serum TSH with normal free T4 and T3 levels in asymptomatic individuals.
• The optimal management strategy for subclinical hyperthyroidism remains controversial.

Purpose:

• To review the current understanding of subclinical hyperthyroidism.
• To discuss the associations between subclinical hyperthyroidism and adverse health outcomes.
• To provide guidance on managing subclinical hyperthyroidism in the absence of definitive treatment evidence.

Summary:

• Observational studies link subclinical hyperthyroidism to increased risks of atrial fibrillation, osteoporosis, cardiovascular disease, and mortality.
• Randomized controlled trials evaluating the benefits of treating subclinical hyperthyroidism are lacking.
• Management algorithms should consider TSH levels and patient-specific risk factors like age, bone health, and cardiac status.

Impact:

• Highlights the need for further research, particularly randomized controlled trials, to establish evidence-based treatment guidelines.
• Emphasizes a personalized approach to managing subclinical hyperthyroidism, balancing potential risks and benefits.
• Informs clinical decision-making for a common condition affecting thyroid hormone regulation.